Integra Therapeutics — Seed · €1.5M

Integra Therapeutics, a Universitat Pompeu Fabra spin-off developing the FiCAT gene-writing platform, closed a new €1.5 million investment led by Columbus Venture Partners, whose managing partner Damià Tormo joined the board. The tranche completes a €6 million seed round that began with €4.5 million raised in December 2021 from AdBio Partners, Invivo Capital and Takeda Ventures.